T-Cell Immunotherapy for Posttransplant EBV-Positive Lymphoma

Half of patients with relapsed/refractory EBV-positive posttransplant lymphoproliferative disorder responded to tabelecleucel, an allogeneic T-cell immunotherapeutic agent.

Epstein–Barr virus (EBV)–positive posttransplant lymphoproliferative disorder (PTLD) is a well-recognized complication of hematopoietic stem-cell transplantation (HSCT) and solid organ transplantation (SOT). Patients who do not respond to a decrease in immunosuppressive therapy, rituximab, or rituximab plus chemotherapy have a very poor prognosis. Investigators now report updated safety and efficacy findings from a phase 3, single-arm, open-label, multicenter, industry-sponsored trial of tabelecleucel, an allogeneic EBV-specific T-cell immunotherapeutic, in patients with relapsed or refractory EBV-positive PTLD.

A dose of 2×10⁶ cells/kg was administered intravenously on days 1, 8, and 15 in 35-day cycles, followed by observation. Any nonresp…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

T-Cell Immunotherapy for Posttransplant EBV-Positive Lymphoma

Topics

Reviewing Author